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Summary
Influenza is a viral respiratory illness that causes high morbidity and significant mortality in 
humans. Costs associated with influenza in terms of human suffering are immeasurable and the 
economic costs are very high. Every year, according to the World Health Organization (WHO), 
5-25% of the global population suffers from infection with influenza and influenza-like viru-
ses and between 500 thousand and one million individuals of all ages die from multiple organ 
complications, irrespective of the geographic location. Influenza vaccination is still neglected 
and the percentage of the global population vaccinated remains low. The first authorization 
for the use of influenza vaccines in humans was issued in 1941. Currently, many varieties of 
influenza vaccine are available, containing either fragments of inactivated influenza virus or 
live vaccine which consists of attenuated virus. The influenza vaccine is most often develo-
ped in chick embryos or less frequently in tissue culture such as MDCK and Vero. A variety of 
inactivated vaccines are registered in Poland. Due to the mutability of the virus, it is not yet 
possible to develop a universal vaccine, nor can the disease be eradicated; however, preven-
tion is possible by inoculating the greatest percentage of the global population. According to 
the WHO, Poland is in the penultimate position in Europe in terms of the percentage of the 
population vaccinated. In the last epidemic season of 2012/2013 only 3.75% of the Polish po-
pulation was immunized.
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A brief history of influenzA vAccines
In the history of influenza, 1933 was a crucial year, mar-
king the discovery and isolation of the influenza virus 
from humans by three British researchers, Wilson Smith, 
Christopher Andrews, and Patrick Laidlaw from the Na-
tional Institute for Medical Research in London [7]. It is 
noteworthy that the institute is also currently a WHO 
Collaborating Centre for Reference and Research on In-
fluenza in Europe [39]. The first attempts to develop an 
influenza vaccine used animals and infected mouse cells 
homogenates, but these were not suitable for use in hu-
mans. In 1937, the introduction of viral propagation in 
chick embryos enabled the production of the vaccine on 
a large scale and this method is still used today. The first 
authorization for the administration of influenza vaccines 
in humans was issued in 1941 based on studies sponsored 
by the Armed Forces of the United States [7,37].
Intensive research on the splitting of the virus occurred 
in the 1960s and ’70s using ether, tri-n-butyl phosphate, 
polysorbate 80. The first authorization for the clinical use 
of a vaccine with split virions, the so-called split vaccine, 
was issued in 1968 and it is still in use in many countries. 
A different type of vaccine was introduced in 1976. This 
vaccine contains only the hemagglutinin and neuramini-
dase subunit, and is known as the subunit vaccine. Both 
the split and subunit vaccines are chromatographically 
pure. Improved purification by zonal centrifugation and 
column chromatography allows for the disposal of most 
of the chicken protein contaminants, resulting in a signi-
ficant reduction in the number of side effects [5,37,39]. 
The introduction of a recombinant virus from a wild-type 
strain produced in conjunction with a laboratory strain 
A/PR/8/34/H1N1/, with good propagation characteri-
stics in the chick embryo, significantly increased the ef-
ficiency of vaccine production [39].
Since 1968, influenza vaccines have been ternary. In ac-
cordance with WHO recommendations, seasonal split 
or subunit inactivated influenza vaccines contain 15 µg 
of hemagglutinin subtype A/H1N1/, 15 µg of subtype 
A/H3N2/, and 15 µg of type B 1 [1,2,3,28]. Companies 
that manufacture influenza vaccine receive these stra-
ins from the WHO [7,39]. Due to the antigenic drift, re-
sulting from point mutations that occur during repli-
cation that generate new variants of influenza virus, 
it is currently difficult to develop a universal vaccine 
against influenza [37,39]. The application of the latest 
molecular biology techniques means that influenza virus 
strains used for current influenza vaccines seem to be 
almost 100% compatible with those that appear in the 
next epidemic season [1,2,3,28]. The 1983–1984 Polish 
study by Lidia Brydak, Wiesław Gall and the now dece-
ased Romuald Semkow on inactivated influenza vaccine 
bears mentioning [7,12]. The National Center for Influ-
enza at the Department of Virology, National Institute 
of Hygiene in Warsaw in cooperation with the Military 
Institute of Epidemiology in Warsaw, obtained first and 
third generation inactivated influenza vaccines [7,12]. 
One was a chromatographically pure inactivated vacci-
ne containing whole virions. The other, also chromato-
graphically pure, was a subunit vaccine containing only 
the hemagglutinin and neuraminidase components [12]. 
These vaccines were developed on a laboratory scale. 
Evaluation of the results of their application in animal 
and controlled human studies showed improved quality 
and effectiveness in comparison with conventional inac-
tivated vaccine that was manufactured by the Serum and 
Vaccine Manufacturing Plant in Krakow [7,12]. A total 
of 1,215 people were vaccinated, with four comparative 
groups of subjects vaccinated with a three-component 
vaccine against influenza with varying levels of purity. 
Anti-neuraminidase and anti-hemagglutinin antibody 
levels were measured. The resulting vaccine was subject 
to state regulation. It was tested by the Department of 
Sera and Vaccines at the National Institute of Hygiene 
in Warsaw. The results of these studies indicated the 
possibility of the manufacture of a modern vaccine that 
would be consistent with WHO standards. Regrettably, 
the results of this pioneering study were not implemen-
ted in large-scale production [7,12]. Poland has not ma-
nufactured an influenza vaccine since 1989; influenza 
vaccines available on the Polish market are imported.
After the first experiments performed in the 1930s, it se-
emed as if it would be impossible to obtain an effective 
vaccine. Vaccines developed for one epidemic were in-
effective against the next and research revealed the exi-
stence of different strains of the virus. Ineffectiveness of 
vaccines was associated with the constant changes in the 
circulating virus, which in this way gained the potential 
to infect individuals who had been resistant during the 
previous epidemic season.
current influenzA vAccines
Two types of vaccine are currently used in the preven-
tion of influenza:
• live attenuated vaccine;
•   various forms of inactivated vaccine: a vaccine conta-
ining the whole virus,
•   split virion vaccine, and highly purified subunit prepa-
rations, containing surface hemagglutinin and neura-
minidase [4,12,39].
Inactivated split or subunit vaccines are the most fre-
quently manufactured. Influenza vaccine does not con-
tain thimerosal [1,2,3,4,7,28,39]. Inactivated influenza 
vaccine is produced mostly in chick embryos and less 
often in MDCK (Madin Darby canine kidney – a cell line 
derived from canine kidney for culturing influenza virus) 
and Vero (green monkey kidney cells) tissue culture. In 
addition, inactivated adjuvanted oil, virosomal, and MF59 
vaccines are also available. These are used in some coun-
tries (for example, in Germany, Italy, Switzerland, En-
gland and Russia) even though the American Committee 
on Immunization Practices (ACIP) does not recommend 
them [1,2,3,4,27,28,39]. The decision on vaccine choice is 
made by the national health authorities. Beyond the ef-139
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forts aimed at a more satisfactory use and distribution of 
currently available vaccines, a number of strategies are 
in place. These are focused on increasing the immunoge-
nicity of vaccines that have already received regulatory 
approval; the aim is to improve the overall quantity and 
quality of available doses. 
The production cycle of split and subunit inactivated in-
fluenza vaccine in chick embryos takes about 6 months. 
This indicates the length of time needed for manufacture. 
Therefore the supply of the vaccine in a timely manner 
must be preceded by an earlier decision of the amount of 
vaccine that is needed. Apart from continually enhanced 
inactivated vaccine, vaccines containing live attenuated 
virus are also used, because they induce an immune ac-
tivation process similar to one that occurs in a natural 
infection. The first trials of the use of vaccines derived 
from cold-adapted mutants were performed in 1938-1939 
by Smorodincev [36]. They contained a virus that had lost 
its pathogenicity for humans due to multiple replication 
in the lung cells of white mice. The mass vaccination with 
cold adapted virus vaccine of schoolchildren in the Soviet 
Union showed a significant reduction in the incidence 
of infection. At this point it is worth mentioning Pol-
ish studies concerning cold adapted virus [6,7]. During 
1980–1990 the National Center for Influenza, National 
Institute of Hygiene in Warsaw, conducted research on 
the adaptation of influenza viruses A/H3N2/ antigen to 
low temperature for replication, with analysis of the an-
tigenic and biochemical properties necessary to deter-
mine their potential as donor genes for obtaining recom-
binant vaccine strains [6,7]. Indicators were designated 
as genetic markers necessary for this type of research 
on emergent and cold-adapted strains that are adapted 
to low temperatures. As a result of these studies there 
were developed two Polish mutants, A/Pol/L/71/ H3N2/ 
and A/Pol/79/85, that can be used as donors of genes 
for recombinant influenza vaccine strains, which was 
confirmed by Professor Dr. L. Döhner of the University 
of Greifswald in Germany [6,7]. It was not until 2003 that 
ACIP and the Centers for Disease Control and Prevention 
(CDC) in Atlanta issued a supplement for the first time, 
for use of the ternary attenuated intranasal influenza 
vaccine FluMist, manufactured by MedImmune, which 
was authorized for use in the United States in June 2003 
[39]. A live attenuated influenza vaccine is not registered 
in Poland [7,8,9]. Although it has been known for decades 
that the vaccine has saved many lives, and its use cur-
rently reduces morbidity and mortality associated with 
influenza, the need to develop a universal vaccine and 
more efficient products remains the dream of virologists. 
Inactivated influenza vaccine has been in use since the 
1940s and has had good safety and efficacy records over 
many years.
PAndemic influenzA vAccines
Intensive research to improve inactivated vaccines is still 
being undertaken with special emphasis on the ability to 
respond to pandemic influenza. During the past decade, 
significant progress occurred in technology of vaccine 
production; this helped either in terms of vaccine man-
ufacture or the improvement of vaccine immunogenicity. 
New routes of administration have also been tested and 
implemented. One proposal was to increase the immu-
nogenicity of the vaccine by adding an effective and safe 
adjuvant, which may also allow a reduction in the amount 
of antigen needed to produce an effective immune re-
sponse. Several different adjuvants have been tested for 
their ability to increase the immunogenicity of protein 
vaccines for a number of different diseases. In the pre-
ventive use of currently available inactivated vaccines in 
individuals who have had previous infection with influ-
enza, a dose of 15 µg of HA of each strain stimulates the 
required level of antibodies (≥ 1:40). 
Provisions harmonizing the vaccines used in the Mem-
ber States entered into force on 1 January 1992, although 
they are not entirely in line with ACIP recommenda-
tions. In the European Union, a vaccine manufactured 
and with regulatory authorization in one Member State 
must be accepted by the other Members [7,28,39]. How-
ever, in accordance with European Union directives (the 
European Directorate for the Quality of Medicines), a 
vaccine registered in the European Union, having OCABR 
approval (the Office of Consumer Affairs and Business 
Regulation), does not require re-examination in EU 
Member States [7,28,39].
recommendAtions for influenzA vAccinAtion
Inactivated split or subunit influenza vaccines can be used 
and should be recommended for all age groups, starting 
from 6 months of age. The latest recommendations from 
the WHO and ACIP [1,2,3,4,7,39] define the clinical indi-
cations for vaccination and identify the high-risk groups 
particularly vulnerable to the occurrence of influenza 
complications. These include, among others, individu-
als who have undergone organ transplantation, healthy 
children from the age of 6 months to 18 years, patients 
in high-risk groups from the age of 6 months onwards, 
patients with any disease that can cause impairment of 
respiratory function including asthma and chronic ob-
turative pulmonary disease (COPD), children and adults 
with chronic cardiovascular or respiratory disease, meta-
bolic diseases, renal failure, hemoglobinopathies, immu-
nodeficiency, pregnant women, residents of homes for 
the elderly, health care workers and chronic care facility 
workers and residents [1,2,3,4,28,39]. However, other in-
dications include individuals who can act as carriers of 
influenza to participants of high-risk groups and those 
healthy individuals who could become a source of infec-
tion for these persons, for example medical profession-
als and care givers of children aged less than 6 months, 
and public servants. Over the course of many epidemic 
seasons the Influenza Virus Research Institute, National 
Center for Influenza NIPH-NIH, provided and dissemi-
nated information to the public that the vaccine should 
be offered throughout the epidemic season, even if there 
is information that the influenza virus is circulating in 140
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the population, refuting one of the myths that vaccina-
tion can only take place in October [34,39]. According to 
the Polish vaccination procedures, it is the doctor who 
decides if vaccination can take place at any given time. 
The following vaccines are available in Poland for the 
2012/2013 influenza epidemic season: Vaxigrip, Fluarix, 
Influvac and IDflu, which is administered intradermally 
(inactivated vaccines should be administered intramus-
cularly) [34]. IDflu contains a total of 27 μg HA/0.1 mL for 
individuals aged 18–59 years, and 45 μg HA/0.1 mL for 
those ≥ 60 years [27]. World Health Organization experts 
provide the influenza strains to manufacturers for vac-
cine production. It should be noted that in the 2012/2013 
epidemic season, two components of the trivalent influ-
enza vaccine, namely the subtype A/H3N2/ and type B, 
have been changed, which rarely happens [4,39]. In ac-
cordance with the recommendations of the WHO, the in-
fluenza vaccine for the current season for the northern 
hemisphere contains:
• A / California / 7/2009 (H1N1) pdm 09-like virus
• A/Victoria/361/2011 (H3N2)-like virus
•   B/Wisconsin/1/2010-like virus (which is similar to the 
Yamagata line B) [27].
future for influenzA vAccines
Since 1968, as mentioned above, influenza vaccine has 
had a ternary composition [4,37]. Currently, studies are 
devoted to the construction of a quadrivalent inacti-
vated influenza vaccine [4,36]. The new vaccine will con-
tain two lines of influenza B virus, because two lines of 
type B influenza viruses are antigenically different: B/
Victoria and B/Yamagata. Vaccination against one type 
of influenza B virus gives limited crossover protection 
against the other type B virus. It is important to take 
into account the difficulty in predicting which subtype 
of the B virus will be circulating in a given epidemic 
season [4]. The widespread use of a future ACIP-recom-
mended quaternary inactivated influenza vaccine would 
help to evaluate its impact and enable the formulation 
of evidence-based conclusions concerning the change 
from the trivalent to the quadrivalent vaccine. It is clear, 
however, that this would depend on many factors such 
as the availability of the vaccine, the percentage of the 
population vaccinated, the effectiveness, and of course 
on the frequency of influenza caused by the type B vi-
rus lines. Moreover, it should be noted that in February 
2012, the US Food and Drug Administration approved 
the intranasal quadrivalent live vaccine (LAIV) FluMist 
Quadrivalent from MedImmune; however, this vaccine 
will only be available in the 2013/2014 epidemiological 
season [27]. 
effectiveness of influenzA vAccines 
It is believed that 70-80% of the population must be vac-
cinated to ensure the necessary herd immunity [1,30,39]. 
The efficacy of vaccination in the elderly is lower than 
that in younger subjects. An anti-hemagglutinin anti-
body titer ³ 1:40 is assumed to be protective [1,7,30,39]. 
Most cases of influenza-associated health complications 
or even death occur in elderly individuals. Therefore, it 
is recommended that they undergo protective seasonal 
vaccination. Individuals aged over 65 years and those suf-
fering from chronic respiratory and cardiovascular dis-
eases, residents of homes for the elderly and care homes 
and for those with chronic disease and similar institutions 
are at risk of complications from influenza and should be 
included in the special vaccination programs [39]. The 
proportion of individuals at high risk increases with age, 
particularly in the elderly (tenfold increase). Prospective 
studies, critical reviews of existing studies and meta-anal-
yses of the available data provide solid scientific evidence 
for a policy of seasonal vaccination of patients in high-
risk groups [27,37, 39]. Based on numerous tests it is esti-
mated that the efficiency of inactivated influenza vaccine 
currently in use in reducing morbidity and mortality in 
high-risk groups ranges from 50% to 70% [7,34,39]. Clin-
ical and economic data accumulated over the years have 
contributed to a more harmonized influenza prevention 
policy in European countries and coherent recommen-
dations from several prestigious scientific immunization 
societies [7, 34,39]. 
Significant health benefits associated with influenza vac-
cination are evident for all age and high-risk groups. In 
Poland, influenza vaccination has been included in the 
immunization schedule since 1994, but solely as a rec-
ommended vaccination [7]. Since 1990 the National Influ-
enza Center has attempted to raise awareness of the role 
of influenza prophylaxis through countrywide lectures, 
educational and scientific articles published in a variety 
of magazines, radio and television interviews, press re-
leases, information leaflets for doctors and patients, as 
well as the publication of three books describing the prob-
lem of influenza (the only books on the subject available 
in Polish) [7,10,11,12,13,14,15,16,17,18,19,20,21,22,23]. It 
must be known, as it has been repeatedly emphasized in 
chapters of the latest edition (2008) of the book by Lidia 
B. Brydak Flu: pandemic flu, myth or real threat?, that the 
occurrence of a pandemic that meets all the long-estab-
lished criteria is inevitable; in fact it is only a matter of 
time. From 1990 to the present the National Center for 
Influenza has performed monitoring studies to evalu-
ate the effectiveness of influenza vaccination not only in 
high-risk groups but also in selected healthy populations, 
including that of Warsaw. These studies have been and 
continue to be conducted in collaboration with several 
medical academic departments, medical universities and 
medical research institutes in Poland and the Centers for 
Disease Control and Prevention in Atlanta [7]. The aim 
of the above study was to present the effectiveness of 
vaccination against influenza measured both in patients 
in high-risk groups and in healthy individuals by eval-
uating the antibody response to the hemagglutinin and 
neuraminidase antigens using international parameters of 
serological response [1,10,11,12,13,14,15,16,17,18,19,20,21
,22,36,38,40,41]. The presentation of case studies derived 
from the above work will be helpful in promoting pre-
vention as well as in encouraging health services staff to 141
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protect not only their patients, but also their loved ones, 
as shown in Table 1.
The study performed by the Influenza Virus Research 
Institute, National Influenza Center NIPH-NIH, together 
with the Institute of Cardiology in Anin, Poland, on sub-
jects with acute cardiovascular events who were vacci-
nated against influenza, informed the European cardiol-
ogy recommendations for influenza vaccination [25,26]. 
The benefits of vaccination of individuals in every age 
group are convincing but even more evident for those 
in high-risk groups irrespective of age. Moreover, there 
are also ethical indications for use of the vaccine in these 
cases.
influenzA vAccine coverAge
In 2008 one of the co-authors of this article, as the first 
one in Poland, provided 30 different options for increas-
ing the percentage of people vaccinated against influenza 
[7], as presented in Table 2.
The effects of multi-organ complications from influenza 
should be considered not only in terms of health, the 
human tragedy in the death of a close relative, which is 
immeasurable, but also in economic terms. Taking cardiac 
transplantation as an example, the cost of this procedure 
is about 140 thousand PLN, excluding the use of immu-
nosuppressive drugs throughout the lifetime of trans-
plant patients. 
In 2012 in Poland a working group was established to de-
velop a National Program for Combating Influenza based 
on a proposal by Prof. Brydak, from 2008 [7].
It is noteworthy that not only family physicians, but phy-
sicians of all specialties, have a crucial role to fulfill in pro-
moting vaccination, and that on a mass scale, especially as 
in the influenza epidemic season of 2012/2013 only 3.75% 
of the total population was immunized, placing Poland in 
the penultimate position in Europe in this respect [8,39].
Despite the fact that both the ACIP and the American Pe-
diatric Society recommend vaccination of children, the 
percentage of vaccinated children remains low, particu-
larly in Poland [1,2,3,4,7]. For example, the percentage of 
those aged 6 months to 4 years who are vaccinated, ap-
proximately 1.4%, is outrageously low, while in those aged 
Table 1. Experimental studies conducted at the Polish National Influenza Center [7]
Children
Children aged 6-35 months, 3-8 years, 9-12 years, 13-20 years
Children with acute lymphoblastic leukemia (ALL), vaccinated at different times after treatment
Children with severe hemophilia
Children with bronchopulmonary dysplasia
Children with glomerulonephritis
Children with chronic renal failure subjected to continuous ambulatory peritoneal dialysis, hemodialysis, and chronic renal failure vaccinated once and twice
Children infected with HIV
Children vaccinated after splenectomy in age groups 0-5 years, 6-10 years, 11-15 years
Children with aplastic anemia
Children with bronchial asthma
Children with inflammatory bowel disease
Adults
Adults aged 21-30, 31-40, 41-50, 51-64, > 64 years
Billeted students of the Military Medical Academy
Chronically ill patients
Patients with acute lymphoblastic leukemia
Patients with chronic renal failure
Renal allograft recipients
Patients infected with HIV at various levels of CD4, with symptoms of AIDS and asymptomatic
Patients with breast cancer
Patients with cancer of the thyroid
Patients with asthma
Patients with chronic obstructive pulmonary disease (COPD)
Patients in young and elderly groups
Patients with acute cardiovascular events
Patients with malignant lymphomas – Hodgkin’s
Patients with lupus
Patients with primary systemic vascular inflammation: Wegener’s granulomatosis142
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Table 2. Opportunities to increase the percentage of people vaccinated against influenza [7]
• Greater acceptance of this form of prevention by doctors
• Implementation of a National Program for Prevention of Influenza
• Inclusion of relevant provisions in health insurance policy
• Deduction against income tax of the cost of the vaccine and vaccination against influenza in all age groups
• Creation of a system of motivation for doctors/nurses to overcome their objections to vaccination
•  Evaluation of the direct and indirect economic impact, involving both pharmaco-economic studies that prove the positive impact of influenza vaccination on 
reducing the cost of treatment in the health system, as well as an analysis of the cost of complications from influenza
•  Public education with new data on the effectiveness of vaccination, cost, and the safety of influenza vaccines with the help of public broadcasters and 
newspapers
• Public education on the effects and risks posed by influenza and especially on the associated complications
• Registration of complications associated with influenza
• Shortening of the distance between the patient and vaccination: doctor – prescription – pharmacy – doctor – vaccination
•  Reimbursement of the cost of influenza vaccination for certain groups at high risk of complications from influenza – the National Influenza Center in Warsaw 
has repeatedly called for this
• Offering influenza vaccination to patients throughout the epidemic season, as recommended by the ACIP in 2000-2007
• Increasing the number of vaccines administered by health care providers, and other entities
• Administering the vaccine to patients hospitalized during routine visits 
• Vaccination of children in kindergartens and schools, in order to reduce the spread of infection and reduce the incidence of disease in high-risk groups
• Vaccination in the workplace, universities, shopping centers, pharmacies, etc.
•  Increasing the proportion of vaccinated individual in residential care facilities such as nursing homes and other chronic care facilities and staff of these 
establishments
•  Compulsory free-of-charge vaccination of health care workers and others in contact with individuals exposed to an increased risk of a severe course of influenza 
infection, thus avoiding additional visits to the doctor
• Written or telephone invitations from primary care facilities concerning the need for influenza vaccination, especially for individuals at high risk
• Establishing vaccination points at additional venues prior to the influenza season such as at the University of the Third Age
•  Development of plans to improve the vaccination availability and infrastructure providing for greater numbers than in the previous epidemic season – Office 
for Health Policy / 16 City Mayors
• Identification of legal and administrative barriers to the organization of vaccination by healthcare institutions and physicians
•  Annual appointment of Influenza Vaccination Task Force at the central, provincial and municipal levels with appropriate legislative regulations for purchasing 
and distribution of vaccine in accordance with the provisions of the Pharmaceutical Law
• Free-of-charge vaccination for hospitalized patients who are at risk for the complications of influenza infection
•  Introduction of influenza vaccination to health programs run by the National Health Fund (such as the programs for prevention of cardiovascular disease, the 
fight against cancer, smoking cessation)
• Public education and information, with particular emphasis on patients at risk for complications of influenza infection (based on [29])
• Free-of-charge vaccination (e.g. funded by the municipality) for school and kindergarten staff
•  Free-of-charge vaccination for certain professional groups (military, police, customs, central government, and other public agency staff of importance for the 
functioning of the State)
• Long-term education – awareness-building campaigns in schools143
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5-14 years the percentage of vaccinations reached only 
2.4% [9]. It is always forgotten that it is children who are at 
high risk for severe complications from influenza, and that 
the universal vaccination of children would generate herd 
immunity, which would reduce the spread of influenza in 
the general population. Nor is the situation satisfactory in 
other age groups, with 3.1% of 15-64 year-olds vaccinated 
[34]. The largest percentage of vaccinated individuals was 
reported for the age group > 65 years, with 14% in the given 
season. For many epidemic seasons now the Office of the 
Marshal in most Provinces has sponsored influenza vacci-
nation for individuals aged >65 years, although despite this 
the level is still low. Regular vaccination is therefore one 
of the few things that can be done to protect individuals 
against the potential risk of serious complications from in-
fluenza and multi-organ complications and consequently 
it should be part of good medical practice.
Marcus Aurelius, the Roman emperor who lived from 121 
to 180, said: A man’s worth is no greater than the worth 
of his ambitions. These words are also valid in the twen-
ty-first century.
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